EQUITY RESEARCH - COMPANY REPORT

MASTER STYLE MASTER TB

THAILAND / SERVICES



- เราคาดว่ากำไรสุทธิ 2Q24 จะโต q-q และ y-y จากการฟื้นตัวของรายได้ของ
 Masterpiece Hospital และส่วนแบ่งกำไรที่สูงขึ้น
- MASTER จะเริ่มรับรู้ส่วนแบ่งจาก V Square ในเดือน มิ.ย. และจะรับรู้ส่วนแบ่งเต็มไตร มาสตั้งแต่ 3Q24 เป็นตันไป
- The Skin Clinic และโรงพยาบาล Dr. Chen น่าจะช่วยหนนผลประกอบการในช่วง 2H24

โรงพยาบาล Dr. Chen ใหม่ตั้งเป้าเท่าทุนใน 4Q24

โรงพยาบาล Dr. Chen ซึ่ง MASTER ถือหุ้น 40% ตั้งอยู่ที่ซอยรามคำแหง 106 โรงพยาบาล ดังกล่าวมีห้องผ่าตัดรวม 6 ห้องและมีการใช้ห้องผ่าตัด 2 ห้องในปัจจุบัน MASTER รับรู้ส่วน แบ่งผลขาดทุน 75,000 บาทจากธุรกิจนี้ใน 1Q24 และกำลังทำการตลาดเพื่อขยายฐานลูกค้า โดยใช้ตัวแทนในการดึงลูกค้าต่างประเทศจากตลาดเช่น ฮ่องกงและจีน นอกจากนี้โรงพยาบาล Dr. Chen ยังใช้หมอจาก MASTER เพื่อให้บริการผ่าตัดเสริมความงามหลายรายการ ควบคู่กับ ความเชี่ยวชาญในการผ่าตัดศัลยกรรมใบหน้าของ Dr. Chen บริษัทวางแผนเปิดห้องผ่าตัดทั้ง 6 ห้องในช่วง 2H24 และตั้งเป้าถึงจุดคุ้มทุนใน 4Q24

เริ่มรับรู้ส่วนแบ่งกำไรจาก V Square ในเดือน มิ.ย. 2024

ปัจจุบัน V Square (ซึ่ง MASTER ถือหุ้น 40%) มี 27 สาขา หลังเปิด 3 สาขาใหม่ในช่วง 1H24 (Central Plaza Nakhon Pathom, Praram 9, และ Mega Bangna) และจะเปิดเพิ่มอีก 5 สาขาในช่วง 2H24 รวมเป็น 8 สาขาใหม่ในปี 2024 บริษัทฯ มีจุดแข็งสำคัญอยู่ที่แพทย์ผิวหนังซึ่ง เชี่ยวชาญในด้านการฉีด นอกจากนี้คลินิกยังกำลังขยายบริการที่ใช้อุปกรณ์เพิ่มขึ้นอาทิเช่น เครื่องกำจัดขน บริษัทฯ มีกลยุทธ์ทางการตลาดสำคัญอยู่ที่การแนะนำแบบปากต่อปาก MASTER จะเริ่มรับรู้ส่วนแบ่งจาก V Square ในเดือน มิ.ย. และจะรับรู้เต็มไตรมาสตั้งแต่ 3Q24 เป็นต้นไป

The Skin Clinic น่าจะช่วยหนุน MASTER ตั้งแต่ 3Q24 เป็นต้นไป

The Skin Clinic (MASTER ถือหุ้น 40%) เป็นผู้เชี่ยวชาญในด้านการดูแลรักษาเส้นผม บริษัท ฯ มี 7 สาขาและให้บริการผ่านโรงพยาบาล 1 แห่ง The Skin Clinic ถือเป็นผู้นำหนึ่งใน 5 บริษัทผู้ให้บริการดูแลรักษาเส้นผมชั้นนำในประเทศไทย ผู้บริหารวางแผนปรับปรุงโรงพยาบาล ดูแลรักษาเส้นผมแห่งแรกบนถนนพระราม 3 ใน 3Q24 พร้อมกำหนดเปิดให้บริการในกลางปี 2025 นอกจากนี้ The Skin Clinic ยังวางแผนขยายการให้บริการรักษาผมร่วงและผมบางโดย จะนำเสนออุปกรณ์ที่ใช้เทคโนโลยีขั้นสูงให้แก่คลินิกอื่น ๆ ในกลุ่มของ MASTER ทั้งนี้ MASTER วางแผนรับรู้ส่วนแบ่งกำไรจาก The Skin Clinic ตั้งแต่ 3Q24 เป็นต้นไป

คาดกำไรจะโต q-q และ y-y ใน 2Q24 ก่อนเร่งตัวขึ้นใน 2H24

เราคาดกำไรสุทธิ์ 2Q24 อยู่ที่ 127 ลบ. (+20% q-q, +56% y-y) จากรายได้ของ Masterpiece Hospital ที่คาดว่าจะฟื้นตัว q-q นอกจากนี้ MASTER ยังวางแผนรับรู้ส่วนแบ่งกำไรจาก 7 บริษัทร่วมใน 2Q24 (เพิ่มขึ้นจาก 6 บริษัทร่วมใน 1Q24) พร้อมส่วนแบ่งกำไรที่คาดว่าจะ เพิ่มขึ้นเป็น 15 ลบ. จาก 10 ลบ. ใน 1Q24 ก่อนเร่งตัวขึ้นในช่วง 2H24 MASTER วางแผนรับรู้ ส่วนแบ่งกำไรเพิ่มขึ้นใน 2H24 โดยจะเพิ่มเป็น 9 และ 13 บริษัทร่วมใน 3Q24 และ 4Q24 ตามลำดับ



BUY

UNCHANGE

TARGET PRICE THB72.00
CLOSE THB64.50
UP/DOWNSIDE +11.6%
PRIOR TP THB72.00
CHANGE IN TP UNCHANGED
TP vs CONSENSUS -4.4%

KEY STOCK DATA

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	1,917	2,326	2,556	2,861
Net profit	416	621	685	763
EPS (THB)	1.58	2.06	2.27	2.53
vs Consensus (%)	-	0.1	(3.8)	(11.6)
EBITDA	586	719	800	902
Recurring net profit	416	621	685	763
Core EPS (THB)	1.58	2.06	2.27	2.53
Chg. In EPS est. (%)	-	nm	nm	nm
EPS growth (%)	(2.2)	30.6	10.3	11.3
Core P/E (x)	40.9	31.3	28.4	25.5
Dividend yield (%)	0.4	1.0	1.4	1.6
EV/EBITDA (x)	28.5	27.0	24.0	20.9
Price/book (x)	5.7	5.6	5.0	4.5
Net debt/Equity (%)	(11.1)	(1.2)	(6.6)	(13.3)
ROE (%)	24.5	19.3	18.7	18.6



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	4.5	(7.2)	(3.2)
Relative to country (%)	8.0	(3.4)	10.5
Mkt cap (USD m)			531
3m avg. daily turnover (USD m)			2.8
Free float (%)			0
Major shareholder	Masch	namadol fa	mily (68%)
12m high/low (THB)		7-	4.00/36.31
Issued shares (m)			301.71

Sources: Bloomberg consensus; FSSIA estimates



Sureeporn Teewasuwet

Fundamental Investment Analyst on Securities; License no. 040694 sureeporn.t@fssia.com, +66 2646 9972

PREPARED BY FSS INTERNATIONAL INVESTMENT ADVISORY SECURITIES CO LTD (FSSIA). ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES CAN BE FOUND AT THE END OF THIS REPORT

Investment thesis

We expect Thailand's cosmetic surgery market to grow by 9.7% CAGR in 2023-30, close to global cosmetic surgery markets. Additionally, the medical tourism trend should support surgery hospitals in Thailand to have a higher revenue mix from international customers, which would in turn support future growth.

MASTER has several strengths. It has earned a good reputation and has become well-known over the past ten years. Given the experience of Dr. Raweewat Maschamadol and other renowned doctors, MASTER has gained customer trust, leading to referrals and positive reviews on social media. It has also expanded and invested in other businesses to further its long-term growth.


Company profile

MASTER is in the cosmetic surgery hospital business under Masterpiece Hospital. Established in 2012, it has 17 operating beds and offers one-stop cosmetic surgery services. MASTER earns revenue from four services, including surgery, skin, hair treatment, and aftercare, with surgery contributing the highest revenue of 81% of total revenue.

www.masterpiecehospital.com

Principal activities (revenue, 2023)

- Surgery 81.0 %
- Skin 7.1 %
- Hair treatment 6.0 %
- Aftercare 3.6 %
- Others 2.3 %




Source: Master Style

Major shareholders

■ Maschamadol family - 68.0 %

■ Others - 32.0 %



Source: Master Style

Catalysts

2024 potential growth drivers include 1) more surgery customers; 2) a higher utilization rate for operating beds, which would drive operating leverage; and 3) the realization of profit and synergies from M&As.

Risks to our call

Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Event calendar

Date	Event
August 2024	2Q24 results announcement

Key assumptions

	2024E	2025E	2026E
Total OR rooms (no.)	17	17	17
Capacity hours (hours)	80,665	80,665	80,665
Operating hours (hours)	58,079	60,499	64,532
Utilization rate (%)	72.0	75.0	80.0


Source: FSSIA estimates

Earnings sensitivity

- For every 5% increase in revenue, we estimate 2024 net profit to rise by 3.9%, and vice versa, all else being equal.
- For every 0.5% increase in GPM, we estimate 2024 net profit to rise by 2%, and vice versa, all else being equal.
- For every 1% increase in SG&A, we estimate 2024 net profit to fall by 3.5%, and vice versa, all else being equal.

Source: FSSIA estimates

Exhibit 1: Timeline to recognize profit sharing from associate companies



Source: MASTER

Exhibit 2: Services and information about V Square




Source: MASTER

Exhibit 3: MASTER – 2Q24E earnings preview

	1Q23	2Q23	3Q23	4Q23	1Q24	2Q24E	Chai	nge	1H23	1H24E	Change
	(THB m)	(q-q%)	(y-y%)	(THB m)	(THB m)	(y-y%)					
Sales	436	459	479	543	468	501	7.0	9.1	895	969	8.3
Cost of sales	182	204	200	198	194	205	5.8	0.4	387	400	3.3
Gross profit	253	255	279	345	274	295	7.9	16.0	508	569	12.0
SG&A	162	158	160	154	160	163	1.8	3.7	320	324	1.2
Operating profit	94	106	128	197	122	142	16.1	34.4	199	265	32.7
Profit sharing	0	0	0	5	10	15	49.2	nm	0	25	nm
Interest expense	3	4	4	3	3	3	0.5	(2.9)	7	7	(3.0)
Tax expense	19	21	25	40	23	28	18.6	33.6	39	51	30.2
Reported net profit	72	81	100	164	106	127	19.5	55.8	153	233	52.4
Core profit	72	81	100	164	106	127	19.5	55.8	153	233	52.4
Key Ratios (%)							(ppt)	(ppt)			
Gross margin	58.2	55.5	58.2	63.6	58.5	59.0	0.5	3.5	56.8	58.8	2.0
SG&A to sales	37.2	34.3	33.5	28.3	34.3	32.6	(1.7)	(1.7)	35.7	33.4	(2.3)
Operating margin	21.5	23.1	26.8	36.3	26.2	28.4	2.2	5.3	22.3	27.3	5.0
Net margin	16.4	17.7	20.8	30.1	22.7	25.3	2.7	7.6	17.1	24.1	7.0
Core margin	16.4	17.7	20.8	30.1	22.7	25.3	2.7	7.6	17.1	24.1	7.0

Sources: MASTER, FSSIA estimates

Exhibit 4: Total revenue




 $Sources: MASTER, FSSIA\ estimates$

Exhibit 6: Gross margin and SG&A to sales




Sources: MASTER, FSSIA estimates

Exhibit 5: Operating hours and utilization rate



Sources: MASTER, FSSIA estimates

Exhibit 7: Net profit and growth



Sources: MASTER, FSSIA estimates

Financial Statements

Master Style

Revenue	Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Gose profit 841 1,132 1,377 1,518 1,737 Other operating process 8 27 33 33 33 37 Operating path (463) (634) (788) (644) (944) (944) (940) 902 903 <t< td=""><td>Revenue</td><td>1,483</td><td>1,917</td><td>2,326</td><td>2,556</td><td>2,861</td></t<>	Revenue	1,483	1,917	2,326	2,556	2,861
Other operating income	Cost of goods sold	(641)	(785)	(949)	(1,038)	(1,159)
Operating DESTITOA	Gross profit	841	1,132	1,377	1,518	1,702
Departation Company	Other operating income	8	27	33	33	37
Depreciation	Operating costs	(463)	(634)	(768)	(844)	(944)
Cooker Company Comp	Operating EBITDA	422	586	719	800	902
Operating EBIT 386 525 642 708 795 Net firancing costs (4) (9) (9) (9) (9) (18) Associaties 0 5 125 137 144 Non-recurring items 0 5 125 137 144 Non-recurring items 0 5 125 137 144 Non-recurring items 363 521 758 836 930 Tax (76) (16) (16) 665 763 Minority interests -<	Depreciation	(35)	(62)	(77)	(92)	(107)
Net financing costs	Goodwill amortisation	0	0	0	0	0
Associaties 0 5 125 137 144 Recurring non-operating income 0 5 125 137 144 Non-recurring felms 0 0 0 0 0 0 Profit before tax 383 521 788 356 930 Tax (76) (105) (136) (150) (157) Profit after tax 366 416 621 685 763 Romingting interest - 0 - 0 - 0 - 0 Preferred dividends - 0 0 0 0 0 0 Preferred dividends - 0 0 0 0 0 0 0 Reported net profit 306 416 621 685 763 Romard temptrift 306 416 621 685 763 Recurring profit 306 416 621 685 763 Recurring profit 306 416 621 685 763 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 416 621 685 763 Per share (THB) - 0 0 0 0 0 0 Recurring profit 306 227 253 226 231 231 Per share (THB) - 0 0 0 0 0 0 Recurring profit 308 224 302 302 302 302 Per share (THB) - 0 0 0 0 0 0 Recurring profit 308 224 302 302 302 302 302 Recurring profit 308 309 30	Operating EBIT	386	525	642	708	795
Recurring from-operating income 0 5 125 137 144 Non-recurring items	Net financing costs	(4)	(9)	(9)	(9)	(9)
Non-recurring items 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	Associates	0	5	125	137	144
Profit before tax 76	Recurring non-operating income	0	5	125	137	144
Tax (76) (105) (136) (150) (167) Profit after tax 306 416 621 685 763 Preferred dividends 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 3 3 4 4 3 2 3 2	Non-recurring items	0	0	0	0	0
Profit after tax 306 416 621 685 763 Minority interests - <td>Profit before tax</td> <td>383</td> <td>521</td> <td>758</td> <td>836</td> <td>930</td>	Profit before tax	383	521	758	836	930
Minority interests 1 c	Tax	(76)	(105)	(136)	(150)	(167)
Preferred dividends -	Profit after tax	306	416	621	685	763
Other items 1 - <th< td=""><td>Minority interests</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></th<>	Minority interests	-	-	-	-	-
Reported net profit 306 416 621 685 763 Non-recurring items & goodwill (net) 306 416 621 685 763 Recurring tem profit 306 416 621 685 763 Per share (THE) 888 206 2.27 2.53	Preferred dividends	-	-	-	-	-
Non-recurring items & goodwill (net) 0	Other items	-	-	-	-	-
Recurring net profit 306 416 621 685 763 Per sahre (THB)	Reported net profit	306	416	621	685	763
Per share (THB) Recurring EPS 1.61 1.58 2.06 2.27 2.53 Reported EPS 0.30 0.27 0.62 0.91 1.01 Diluted shares (used to calculate per share data) 190 264 302 302 302 Growth	Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring EPS* 1.61 1.58 2.06 2.27 2.53 Reported EPS 1.61 1.58 2.06 2.27 2.53 DPS 0.30 0.27 0.62 0.91 1.01 Diluted shares (used to calculate per share data) 190 264 302 302 302 Toward Reverue (%) 124.8 2.93 21.4 9.9 11.9 Operating EBITOA (%) 73.9 39.1 22.5 11.3 12.8 Operating EBITOA (%) 82.7 35.9 22.3 10.3 11.3 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EPT (%) 56.7 59.1 59.5 59.4 59.5 Gross margin inc. depreciation (%) 56.7 59.1 62.5 59.4 59.5 Gross margin sex. depreciation (%) 59.1 26.3 <td< td=""><td>Recurring net profit</td><td>306</td><td>416</td><td>621</td><td>685</td><td>763</td></td<>	Recurring net profit	306	416	621	685	763
Reported EPS 1.61 1.58 2.06 2.27 2.53 DPS 0.30 0.27 0.62 0.91 1.01 Dibluded shares (used to calculate per share data) 190 264 302 302 302 Growth Revenue (%) 124.8 29.3 21.4 9.9 11.9 Operating EBIT (%) 82.7 35.9 22.3 10.3 12.8 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 50.7 59.1 59.2 59.4 59.5 Gross margin inc. depreciation (%) 56.7 59.1 62.3 62.5 63.0 32.	· /					
DPS 0.30 0.27 0.62 0.91 1.01 Diluted shares (used to calculate per share data) 190 264 302 302 302 Growth Fevenue (%) 124.8 29.3 21.4 9.9 11.9 Operating EBITOA (%) 73.9 39.1 22.5 11.3 12.8 Operating EBIT (%) 82.7 35.9 22.3 10.3 12.3 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EBIT morigin (%) 59.1 62.3 62.5 63.0 63.2 Gross margin inc. depreciation (%) 59.1 62.3 62.5 63.0 63.2	_					
Diluted shares (used to calculate per share data) 190 264 302	•					
Growth Revenue (%) 124.8 29.3 21.4 9.9 11.9 Operating EBITDA (%) 73.9 39.1 22.5 11.3 12.8 Operating EBIT (%) 82.7 35.9 22.3 10.3 12.3 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EBIT CRagin in inc. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 26.1 27.4 27.6 26.7 27.7 27.8						
Operating EBITDA (%) 73.9 39.1 22.5 11.3 12.8 Operating EBIT (%) 82.7 35.9 22.3 10.3 12.3 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Apported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating EPG (%) 56.7 59.1 59.2 59.4 59.5 Gross margin inc. depreciation (%) 56.7 59.1 62.3 62.5 63.0 63.2 Gross margin inc. depreciation (%) 28.4 30.6 30.9 31.3 31.5 Gross margin (%) 26.1 27.4 27.6 27.7 27.8 Operating EBIT margin (%) 20.1 18.0 18.0 18.0 Operating EBIT margin (%) 18.6 17.0 30.0 40.0 18.0 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.	· · · · · · · · · · · · · · · · · · ·	190	264	302	302	302
Operating EBIT (%) 82.7 35.9 22.3 10.3 12.3 Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating performance Gross margin ex. depreciation (%) 56.7 59.1 59.2 59.4 59.5 Gross margin ex. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBIT Margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 18.0 Interest cover (X) 10.2	Revenue (%)	124.8	29.3	21.4	9.9	11.9
Recurring EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating performance Gross margin inc. depreciation (%) 56.7 59.1 59.2 59.4 59.5 Gross margin exc. depreciation (%) 56.7 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 3.1 37	Operating EBITDA (%)	73.9	39.1	22.5	11.3	12.8
Reported EPS (%) 0.0 (2.2) 30.6 10.3 11.3 Operating performance Use of the peciation (%) 56.7 59.1 59.2 59.4 59.5 Gross margin inc. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Interest cover (X) 13.6 41.1 42.8 42.0 41.8 Debtor days 3.4 64.9 62.6 47.2 47.0 Operating EBITDA margin (%) 82.1 37.7 33.0	Operating EBIT (%)	82.7	35.9	22.3	10.3	12.3
Operating performance Gross margin inc. depreciation (%) 56.7 59.1 59.2 59.4 59.5 Gross margin exc. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 3.4.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROE (%) 107.4 24.5 19.3 </td <td>Recurring EPS (%)</td> <td>0.0</td> <td>(2.2)</td> <td>30.6</td> <td>10.3</td> <td>11.3</td>	Recurring EPS (%)	0.0	(2.2)	30.6	10.3	11.3
Gross margin inc. depreciation (%) 56.7 59.1 59.2 59.4 59.5 Gross margin exc. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 3.4 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4	Reported EPS (%)	0.0	(2.2)	30.6	10.3	11.3
Gross margin exc. depreciation (%) 59.1 62.3 62.5 63.0 63.2 Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%)	Operating performance					
Operating EBITDA margin (%) 28.4 30.6 30.9 31.3 31.5 Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 <	Gross margin inc. depreciation (%)	56.7	59.1	59.2	59.4	59.5
Operating EBIT margin (%) 26.1 27.4 27.6 27.7 27.8 Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted <td>Gross margin exc. depreciation (%)</td> <td>59.1</td> <td>62.3</td> <td>62.5</td> <td>63.0</td> <td>63.2</td>	Gross margin exc. depreciation (%)	59.1	62.3	62.5	63.0	63.2
Net margin (%) 20.7 21.7 26.7 26.8 26.7 Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 20.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted * Pre-exceptional, pre-goodwill and fully diluted 10.6 136 161	Operating EBITDA margin (%)	28.4	30.6	30.9	31.3	31.5
Effective tax rate (%) 19.9 20.1 18.0 18.0 18.0 Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087	Operating EBIT margin (%)	26.1	27.4	27.6	27.7	27.8
Dividend payout on recurring profit (%) 18.6 17.0 30.0 40.0 40.0 Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 <	Net margin (%)	20.7	21.7	26.7	26.8	26.7
Interest cover (X) 102.2 62.2 81.7 90.8 101.7 Inventory days 26.8 41.1 42.8 42.0 41.8 Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 After	Effective tax rate (%)	19.9	20.1	18.0	18.0	18.0
Inventory days 26.8	Dividend payout on recurring profit (%)	18.6	17.0	30.0	40.0	40.0
Debtor days 0.9 1.1 1.1 1.0 0.9 Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	Interest cover (X)	102.2	62.2	81.7	90.8	101.7
Creditor days 34.7 64.9 62.6 47.2 47.0 Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	Inventory days	26.8	41.1	42.8	42.0	41.8
Operating ROIC (%) 115.1 37.7 33.0 43.0 46.8 ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	Debtor days	0.9	1.1	1.1	1.0	0.9
ROIC (%) 82.1 25.8 20.2 19.2 20.4 ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88		34.7	64.9	62.6	47.2	47.0
ROE (%) 107.4 24.5 19.3 18.7 18.6 ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88						
ROA (%) 40.0 18.5 16.3 16.1 16.2 * Pre-exceptional, pre-goodwill and fully diluted Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88			25.8	20.2	19.2	20.4
Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	ROE (%)		24.5	19.3	18.7	
Revenue by Division (THB m) 2022 2023 2024E 2025E 2026E Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	ROA (%)	40.0	18.5	16.3	16.1	16.2
Surgery 1,194 1,553 1,908 2,087 2,337 Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	* Pre-exceptional, pre-goodwill and fully diluted					
Skin 106 136 161 185 210 Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88	Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Hair treatment 90 115 136 154 175 Aftercare 62 70 75 82 88			1,553	1,908	2,087	2,337
Aftercare 62 70 75 82 88						
On the Market Of the FOOIA and the second of		62	70	75	82	88

Sources: Master Style; FSSIA estimates

Financial Statements

Master Style

iviaster Style			22215		*****
Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	306	416	621	685	763
Depreciation Associates & minorities	35 0	62 0	77 0	92 0	107 0
Other non-cash items	0	(5)	(125)	(137)	(144)
Change in working capital	(100)	74	(38)	18	9
Cash flow from operations	242	547	534	658	735
Capex - maintenance		J-1/	-	-	755
Capex - new investment	(413)	(2,179)	(673)	(171)	(107)
Net acquisitions & disposals	(1.0)	(2,)	(0.0)	-	()
Other investments (net)	_	_	_	_	_
Cash flow from investing	(413)	(2,179)	(673)	(171)	(107)
Dividends paid	(263)	(99)	(189)	(274)	(305)
Equity finance	198	2,270	38	0	0
Debt finance	159	(11)	(2)	(2)	(2)
Other financing cash flows	(1)	2	Ô	Ó	1
Cash flow from financing	93	2,161	(153)	(275)	(306)
Non-recurring cash flows	-	-	. ,	` -	` -
Other adjustments	0	0	0	0	0
Net other adjustments	(5)	0	0	0	0
Movement in cash	(83)	529	(292)	212	321
Free cash flow to firm (FCFF)	(162.06)	(1,618.40)	(124.27)	501.30	641.76
Free cash flow to equity (FCFE)	(18.91)	(1,641.98)	(140.56)	485.65	626.33
Per share (THB)					
FCFF per share	(0.54)	(5.36)	(0.41)	1.66	2.13
FCFE per share	(0.06)	(5.44)	(0.47)	1.61	2.08
Recurring cash flow per share	1.80	1.79	1.90	2.12	2.40
Balance Sheet (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Tangible fixed assets (gross) Less: Accumulated depreciation	498 (73)	1,242 (339)	1,578 (366)	1,665 (395)	1,740 (427)
Tangible fixed assets (net)	(73) 424	(339) 903	1,211	(395) 1,270	1,313
Intangible fixed assets (net)	7	903 7	7	7	7
Long-term financial assets	8	15	15	15	15
Invest. in associates & subsidiaries	0	362	1,861	2,019	2,060
Cash & equivalents	98	627	335	547	868
A/C receivable	5	7	6	7	8
Inventories	63	101	104	114	127
Other current assets	166	1,136	302	281	315
Current assets	331	1,871	748	949	1,317
Other assets	177	480	233	256	286
Total assets	947	3,637	4,074	4,515	4,998
Common equity	404	2,991	3,461	3,872	4,330
Minorities etc.	0	0	0	0	0
Total shareholders' equity	404	2,991	3,461	3,872	4,330
Long term debt	291	294	292	291	289
Other long-term liabilities	3	5	5	5	6
Long-term liabilities	294	298	297	296	295
A/C payable	148	260	210	230	257
Short term debt	15	2	2	2	2
Other current liabilities	86	86	105	115	114
Current liabilities	249	348	316	347	373
Total liabilities and shareholders' equity	947	3,637	4,074	4,515	4,998
Net working capital	0	898	98	57	78
Invested capital	616	2,664	3,424	3,623	3,758
* Includes convertibles and preferred stock which is being tre	eated as debt				
Per share (THB)					
Book value per share	2.12	11.33	11.47	12.83	14.35
Tangible book value per share	2.09	11.30	11.45	12.81	14.33
Financial strength					
Net debt/equity (%)	51.7	(11.1)	(1.2)	(6.6)	(13.3)
Net debt/total assets (%)	22.1	(9.1)	(1.0)	(5.6)	(11.6)
Current ratio (x)	1.3	5.4	2.4	2.7	3.5
CF interest cover (x)	105.2	64.0	57.8	71.6	80.5
Valuation	2022	2023	2024E	2025E	2026E
		40.9	31.3	28.4	25.5
Recurring P/E (x) *	40.0			31.7	28.5
Recurring P/E (x) * Recurring P/E @ target price (x) *	40.0 44.7		35.0		
Recurring P/E @ target price (x) *	44.7	45.7	35.0 31.3		
Recurring P/E @ target price (x) * Reported P/E (x)	44.7 40.0	45.7 40.9	31.3	28.4	25.5
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	44.7 40.0 0.5	45.7 40.9 0.4	31.3 1.0	28.4 1.4	25.5 1.6
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	44.7 40.0 0.5 30.4	45.7 40.9 0.4 5.7	31.3 1.0 5.6	28.4 1.4 5.0	25.5 1.6 4.5
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	44.7 40.0 0.5 30.4 30.9	45.7 40.9 0.4 5.7 5.7	31.3 1.0 5.6 5.6	28.4 1.4 5.0 5.0	25.5 1.6 4.5 4.5
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	44.7 40.0 0.5 30.4 30.9 29.6	45.7 40.9 0.4 5.7 5.7 28.5	31.3 1.0 5.6 5.6 27.0	28.4 1.4 5.0 5.0 24.0	25.5 1.6 4.5 4.5 20.9
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	44.7 40.0 0.5 30.4 30.9	45.7 40.9 0.4 5.7 5.7	31.3 1.0 5.6 5.6	28.4 1.4 5.0 5.0	25.5 1.6 4.5 4.5

Sources: Master Style; FSSIA estimates

Disclaimer for ESG scoring

ESG score	Methodology	y			Rating						
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process base from the annu	d on the comulated and the comulated the comulated and the comulat	transparent, rules-based opanies' Total Sustainabili al Corporate Sustainabilit anies within each industry	ty Scores resulting y Assessment (CSA).	Sustainability Assessment (CSA) for DJSI. Companies with an S&P Glo						
Sustainability Investment List (THSI) by The Stock Exchange of Thailand (SET)	managing but Candidates m 1) no irregula float of >150 up capital. So 70%; 2) inder wrongdoing re	siness with tr nust pass the r trading of th shareholders ome key disqueendent direct elated to CG,	ility in Environmental and ansparency in Governanc preemptive criteria, with the board members and explication of the control	te, updated annually. two crucial conditions: ecutives; and 2) free tust be >15% of paid-) CG score of below n; 3) executives' npacts; 4) equity in	during the assessment year. The scoring will be fairly weighted against nature of the relevant industry and materiality.						
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by th	ne Thai IOD, T). The result	h in sustainable developm with support from the Stor ts are from the perspective s.	ck Exchange of	Good (80-89), 3 and not rated for equitable treatr	3 for Good (70 or scores below nent of shareh 5%); 4) disclo	ories: 5 for Exce 1-79), 2 for Fair (w 50. Weighting solders (weight 2 sure & transpare	60-69), 1 for F s include: 1) th 25% combined	lass (60-69), ne rights; 2) and); 3) the role of		
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment are transparent a out of five the criteria cover date (45%), a circulation of suexercised. The and verifiability,	incorporated nd sufficiently cCG compon AGM proced and after the r ifficient informa second assess and 3) openne	which shareholders' rights into business operations y disclosed. All form impo ents to be evaluated annuures before the meeting (meeting (10%). (The first as tion for voting; and 2) facilitatines 1) the ease of attending mess for Q&A. The third involves es, resolutions and voting resi	and information is rtant elements of two ually. The assessment 45%), at the meeting issesses 1) advance on how voting rights can be eetings; 2) transparency is the meeting minutes that	of two ssment setting						
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishmen policies. The (Companies de Declaration of I. Certification, ind managers and	t of key contr Certification is ciding to becon ntent to kick off cluding risk ass employees, est	Checklist include corruption of the monitoring are sood for three years. The a CAC certified member state an 18-month deadline to subsessment, in place of policy an ablishment of whistleblowing of a stakeholders.)	and developing of art by submitting a mit the CAC Checklist for d control, training of	passed Checkli	st will move fo se members a	ed by a committe or granting certifi re twelve highly chievements.	cation by the (CAC Council		
Morningstar Sustainalytics	based on an a	assessment of aged. Sources	sk rating provides an over of how much of a compan sto be reviewed include corpo			score is the sun higher ESG risk		ed risk. The			
		mpany feedbac	her media, NGO reports/websi k, ESG controversies, issuer f iews.		NEGL Low Medium High Severe						
	.,,,	. , . ,			0-10	10-20	20-30	30-40	40+		
ESG Book	positioned to the principle of helps explain	outperform o of financial m future risk-ad g features wi	sustainable companies that wer the long term. The me ateriality including informa djusted performance. Mate th higher materiality and ready basis.	ethodology considers ation that significantly eriality is applied by	scores using m	ateriality-base	ated as a weigh d weights. The s dicating better p	score is scaled			
<u>MSCI</u>			measure a company's mand laggards according to t						nethodology to		
	AAA	8.571-10.00	0								
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most si	gnificant ESG ris	sks and opportuniti	es			
	Α	5.714-7.142	2								
	BBB	4.286-5.713	Average:	a mixed or unexception industry peers	al track record of ma	anaging the mos	t significant ESG ri	sks and opportu	nities relative to		
	ВВ	2.857-4.285									
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure to	manage significa	nt ESG risks			
A	CCC	0.000-1.428		alla inte	Election 1 of 1	-C(ii)		fall to			
Moody's ESG solutions	believes that	a company ir	gree to which companies to integrating ESG factors into or shareholders over the n	o its business model and							
Refinitiv ESG rating	based on pub	olicly available	and objectively measure as and auditable data. The ta publicly. (Score ratings as	score ranges from 0 to	100 on relative E	SG performan	ce and insufficie	ent degree of t			
S&P Global			re is a relative score measing the same industry class			•	of ESG risks, op	portunities, ar	nd impacts		
Bloomberg	ESG Score		score is based on Bloom	nberg's view of ESG fina	ancial materiality.	The score is a	a weighted gene	ralized mean	(power mean)		
		ESG Score Bloomberg score evaluating the company's aggregated Environmental, Social and Governance (ESG) performance. The score is based on Bloomberg's view of ESG financial materiality. The score is a weighted generalized mean (power mean) of Pillar Scores, where the weights are determined by the pillar priority ranking. Values range from 0 to 10; 10 is the best. ESG Disclosure Score Disclosure of a company's ESG used for Bloomberg ESG score. The score ranges from 0 for none to 100 for disclosure of									

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

GENERAL DISCLAIMER

ANALYST(S) CERTIFICATION

Sureeporn Teewasuwet FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
12-Dec-2023	BUY	71.00	27-Feb-2024	BUY	82.00	19-Mar-2024	BUY	72.00

Sureeporn Teewasuwet started covering this stock from 12-Dec-2023

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Master Style	MASTER TB	THB 64.50	BUY	Downside risks to our P/E-based TP include 1) increased competition; 2) a pandemic that results in a lockdown; 3) lower-than-expected utilization rate of new operating beds; 4) higher-than-expected doctor costs and expenses; and 5) a loss contribution from the acquired units.

Source: FSSIA estimates

Additional Disclosures

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 25-Jun-2024 unless otherwise stated.

RECOMMENDATION STRUCTURE

Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

Industry Recommendations

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

Country (Strategy) Recommendations

Overweight (O). Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Neutral (N). Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

Underweight (U). Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.